- Conditions
- Mild to Moderate Alzheimer's Disease
- Interventions
- CT1812, Placebo
- Drug
- Lead sponsor
- Cognition Therapeutics
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Stamford, Connecticut + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2569–2592
of 12,568
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Secondary Hypogonadism, Sexual Dysfunction, Erectile Dysfunction
- Interventions
- fispemifene, Placebo
- Drug · Other
- Lead sponsor
- NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 16
- States / cities
- Little Rock, Arkansas • San Diego, California • Bradenton, Florida + 12 more
- Conditions
- Stage III Adult Soft Tissue Sarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage IVA Adult Soft Tissue Sarcoma, Stage IIB Adult Soft Tissue Sarcoma, Stage IIC Adult Soft Tissue Sarcoma
- Interventions
- doxorubicin, filgrastim, ifosfamide, biological response modifier therapy, brachytherapy, chemotherapy, colony-stimulating factor therapy, conventional surgery, cytokine therapy, intraoperative radiotherapy, radiation therapy, surgery
- Drug · Procedure
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 216
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 165 more
- Conditions
- NSCLC, Gastric Cancer
- Interventions
- PEGPH20, Pembrolizumab
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 25 more
- Conditions
- Urinary Tract Infections
- Interventions
- SpeediCath, Conveen Uncoated
- Device
- Lead sponsor
- Coloplast A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 12
- States / cities
- Downey, California • San Jose, California • Englewood, Colorado + 9 more
- Conditions
- Candida Vulvovaginitis
- Interventions
- Ibrexafungerp, Placebo
- Drug
- Lead sponsor
- Scynexis, Inc.
- Industry
- Eligibility
- 12 Years and older · Female only
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 20 more
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
- Interventions
- Olutasidenib + TMZ
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 12 Years to 39 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2035
- U.S. locations
- 11
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more
- Conditions
- Chronic Graft-versus-host Disease
- Interventions
- R348 Ophthalmic Solution, 0.2%, R348 Ophthalmic Solution, 0.5%, Placebo Ophthalmic Solution
- Drug · Other
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 2
- States / cities
- Plantation, Florida • Boston, Massachusetts
- Conditions
- Breast Cancer
- Interventions
- Letrozole, Ribociclib, Placebo
- Drug
- Lead sponsor
- Qamar Khan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 13
- States / cities
- Little Rock, Arkansas • Duarte, California • Santa Ana, California + 9 more
- Conditions
- Migraine
- Interventions
- Fremanezumab
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D LLC
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 499 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 32
- States / cities
- Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- NVA237 100 µg, Placebo, NVA237 200 µg
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 281 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 16
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Wheat Ridge, Colorado + 12 more
- Conditions
- Ulcerative Colitis
- Interventions
- Catered diet, Diet guidance sessions, Dietary counseling, Feedback sessions
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Irritable Bowel Syndrome With Constipation (IBS-C)
- Interventions
- SYN-010 21 mg, SYN-010 42 mg, Placebo
- Drug
- Lead sponsor
- Theriva Biologics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Soft Tissue Injuries
- Interventions
- RF and PEMF, Ultrasound
- Device
- Lead sponsor
- Venus Concept
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Plaque Psoriasis
- Interventions
- Ixekizumab, Guselkumab, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 82 more
- Conditions
- Advanced Cancer
- Interventions
- BMS-986249, Nivolumab, Ipilimumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 19
- States / cities
- Aurora, Colorado • Denver, Colorado • Miami, Florida + 15 more
- Conditions
- COVID-19 Pneumonia
- Interventions
- Remdesivir, Tocilizumab, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 649 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Chula Vista, California • Irvine, California + 33 more
- Conditions
- Leukemia
- Interventions
- docetaxel
- Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 21 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 200
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 148 more
- Conditions
- Rosacea
- Interventions
- IDP-115, Vehicle
- Drug
- Lead sponsor
- Dow Pharmaceutical Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 10
- States / cities
- Huntsville, Alabama • San Diego, California • Vallejo, California + 7 more
- Conditions
- Retinal Vein Occlusion
- Interventions
- pegaptanib sodium
- Drug
- Lead sponsor
- Eyetech Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 35
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
- Conditions
- HIV Infections
- Interventions
- Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 1,750 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1997
- U.S. locations
- 85
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Diego, California + 43 more
- Conditions
- Atrial Fibrillation, Stroke
- Interventions
- WATCHMAN Device, Warfarin
- Device · Drug
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 41
- States / cities
- Gilbert, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
- Conditions
- Neuroendocrine Neoplasm
- Interventions
- Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Peposertib
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 5
- States / cities
- Duarte, California • Miami, Florida • Lexington, Kentucky + 2 more
- Conditions
- Healthy Adult
- Interventions
- 5 Methoxy N,N Dimethyltryptamine, GH001 Aerosol Delivery System
- Drug · Device
- Lead sponsor
- GH Research Ireland Limited
- Industry
- Eligibility
- 21 Years to 64 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida